Page 43 - วารสารกรมการแพทย์แผนไทยฯ ปีที่ 14 ฉบับที่ 3
P. 43

261




              μ“√“ß∑’Ë 2 ¬“√—°…“‚√§∑“ß®‘쇫™∑’˺à“π°“√√—∫√Õß®“° ”π—°ß“πÕ“À“√·≈–¬“¢Õß À√—∞Õ‡¡√‘°“ (US Food and Drug
                       Administration: FDA)










































                                                       [4]
              ∑’Ë¡“: ¥—¥·ª≈ßμ“√“ß¡“®“° Hoffman and Mathew (2008)
              Õ—°…√¬àÕ: GAD, ‚√§«‘μ°°—ß«≈∑—Ë«‰ª; PD, ‚√§·æπ‘°; PTSD, ‚√§‡§√’¬¥À≈—߇º™‘≠‡Àμÿ√⓬; PB, ‚√§°≈—«; OCD, ‚√§¬È”§‘¥¬È”∑”;
                     AD, ‚√§´÷¡‡»√â“∑’ˇªìπ√à«¡°—∫‚√§«‘μ°°—ß«≈; MDD, ‚√§´÷¡‡»√â“Õ¬à“ß√ÿπ·√ß; PMDD, ‚√§‡§√’¬¥°àÕπ¡’ª√–®”‡¥◊Õπ;
                     STA, ‚√§«‘μ°°—ß«≈„π√–¬– —Èπ Ê; ETOHw, ‚√§¢“¥ ÿ√“; Insomnia, ‚√§πÕπ‰¡àÀ≈—∫


              ¬—ß “¡“√∂π—∫Õ¬Ÿà„π‡°≥±å¡“μ√∞“π¢Õß°“√ √â“ß  ´àÕπ À≈’°Àπ’ ·≈–À¬ÿ¥π‘Ëß°—∫∑’ˇæ◊ËÕª√–‡¡‘π
                                    [6]
              ·∫∫®”≈Õß„π —μ«å∑¥≈Õ߉¥â                     ∂“π°“√≥å ´÷Ë߇ªìπæƒμ‘°√√¡∑’Ë¡’§«“¡„°≈⇧’¬ßμàÕ
                                                                            [10]
                  °“√®”·π°·∫∫®”≈Õß„π°“√»÷°…“‚√§«‘μ°      ∑ƒ…Æ’°“√‡°‘¥‚√§„π§π
              °—ß«≈„π —μ«å∑¥≈Õß “¡“√∂·∫àßÕÕ°‡ªìπ 1) Condi-    EPM ‡ªìπ·∫∫®”≈Õß∑“ßæƒμ‘°√√¡¢Õß‚√§
              tioned response ‡™àπ Vogel conflict, Four-plate  «‘μ°°—ß«≈∑’Ëπ—°«‘®—¬π‘¬¡„™â°—π¡“°∑’Ë ÿ¥ ‡√‘Ë¡π”¡“
                                                                                         [11]
              test, Geller-Seifter conflict ·≈– 2) Uncondi-  ∑¥ Õ∫„πÀπŸ·√∑‡ªìπ§√—Èß·√°„πªï 1985  ·∫∫
              tioned response ‡™àπ Elevated Plus Maze    ®”≈Õßπ’È¡’≈—°…≥–‡ªìπ‡§√◊ËÕßÀ¡“¬∫«° ´÷Ëߪ√–°Õ∫

              (EPM), Dark/Light Box (DLB) ·≈– Open Field  ‰ª¥â«¬·¢πªî¥∑’ËÀ—πÀπⓇ¢â“À“°—π 2 ¥â“π ·≈–·¢π
              Test (OFT)  —μ«å∑¥≈Õß®–· ¥ßªØ‘°‘√‘¬“°“√À≈∫  ‡ªî¥Õ’° 2 ¥â“π (√Ÿª∑’Ë 1A) μ—«¢Õß·∫∫®”≈Õß®–¬°
   38   39   40   41   42   43   44   45   46   47   48